We are live on ! Find out more
IRON icon

Disc Medicine

50 hedge funds and large institutions have $33.7M invested in Disc Medicine in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 16 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

52% more call options, than puts

Call options by funds: $126K | Put options by funds: $83K

0.2% less ownership

Funds ownership: 2.2%2% (-0.2%)

12% less funds holding

Funds holding: 5750 (-7)

15% less capital invested

Capital invested by funds: $39.6M → $33.7M (-$5.86M)

32% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 19

50% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 16

Holders
50
Holders Change
-7
Holders Change %
-12.28%
% of All Funds
0.84%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
13
Increased
8
Reduced
16
Closed
19
Calls
$126K
Puts
$83K
Net Calls
+$43K
Net Calls Change
+$16K

IRON Hedge Fund Activity: Q2 2022 in Review

50 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Disc Medicine (IRON) for Q2 2022, worth a combined $33.7M — down 15% from $39.6M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of IRON and 13 opened new positions — a net loss of 6 holders — while 16 trimmed existing stakes and 8 added.

The largest buyer was K2 Principal Fund, opening a new position worth an estimated $432K. The largest seller was BlackRock, cutting an estimated $1.6M.

  • 50 institutional investors held Disc Medicine (IRON) as of Q2 2022, down from 57 in Q1 2022.
  • Funds reported $33.7M of Disc Medicine stock for Q2 2022, down 15% quarter-over-quarter.
  • 13 funds opened new Disc Medicine positions in Q2 2022 and 19 closed out, a net change of -6 holders.
  • The largest Disc Medicine buyer in Q2 2022 was K2 Principal Fund, an estimated $432K added.
  • The largest Disc Medicine seller in Q2 2022 was BlackRock, an estimated $1.6M sold.

Based on aggregated 13F filings for Q2 2022.